Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab (CURE)

NCT03306446 Phase 4 UNKNOWN

This is a prospective, longitudinal, multicenter study conducted in a cohort of patients with early CD. This study will not change the patient/physician relationship.

Details

Lead sponsor	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Phase	Phase 4
Status	UNKNOWN
Enrolment	203
Start date	2015-03-17
Completion	2025-03

Conditions

• CD

Interventions

• Start adalimumab in monotherapy

Primary outcomes

• Sustained deep remission rate — 12 months
  Number of patients with sustained deep remission at one year

Countries

Belgium, France